StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX – Free Report) in a research note issued to investors on Friday morning. The firm issued a hold rating on the medical equipment provider’s stock.
IRIDEX Stock Performance
Shares of IRIX stock opened at $1.67 on Friday. IRIDEX has a fifty-two week low of $1.27 and a fifty-two week high of $3.65. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54. The stock’s fifty day moving average is $1.66 and its two-hundred day moving average is $1.84. The firm has a market capitalization of $27.79 million, a P/E ratio of -2.49 and a beta of 0.81.
IRIDEX (NASDAQ:IRIX – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. The business had revenue of $11.58 million during the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. During the same period last year, the firm posted ($0.11) EPS.
About IRIDEX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Read More
- Five stocks we like better than IRIDEX
- What is the Australian Securities Exchange (ASX)
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- What Are Dividend Contenders? Investing in Dividend Contenders
- These 3 Quirky ETFs May Be Strong Plays in 2025
- Are Penny Stocks a Good Fit for Your Portfolio?
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.